Introduction
Cytotoxic T lymphocytes (CTLs) play an important role in the elimination of virus-infected cells, which they recognize through the detection of virus-derived peptides presented at the cell surface by MHC class I (MHC I) molecules. The viral peptides result from proteasomal degradation of proteins in the cytosol and are translocated by the Transporter associated with Antigen Processing (TAP) into the endoplasmic reticulum (ER), where they are loaded onto newly synthesized MHC I molecules. As an alternative to presentation of peptides derived from endogenously synthesized proteins, specialized antigen presenting cells, such as dendritic cells, may take up viral proteins from their environment and present peptides derived from those proteins to CTLs. This process of presenting exogenous antigens via MHC I molecules is known as cross-presentation; the routes by which exogenous antigens reach MHC I molecules are poorly understood. As will be discussed, viral inhibitors of antigen presentation are powerful instruments to decipher the routing of antigens in both direct and cross-presentation.
DNA viruses with a large genome coding capacity, such as herpesviruses, have proven particularly adept at preventing CTL recognition through the actions of dedicated immune evasion proteins. The family Herpesviridae, which is divided into the subfamilies Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae (whose members are often referred to as alphaherpesviruses, betaherpesviruses, and gammaherpesviruses, respectively), is estimated to have emerged roughly 400 million years ago [1] . The long co-evolution of these viruses with their host is believed to have contributed to extensive adaptation of these pathogens to their respective hosts.
The vast majority of the human population is infected with one or more of the eight known human herpesviruses, namely herpes simplex viruses types 1 and 2 (HSV-1 and HSV-2), varicella-zoster virus (VZV), human cytomegalovirus (HCMV), human herpesviruses 6 and 7 (HHV-6 and HHV-7), Epstein-Barr virus (EBV), and Kaposi's sarcoma-associated herpesvirus (KSHV) [2] . Herpesvirus infections usually cause only mild symptoms, but serious complications can arise, particularly in immunocompromised individuals. In addition, HCMV is the most common viral cause of congenital defects, and EBV and KSHV are associated with the development of several malignancies [3] .
A hallmark of herpesviruses is their ability to establish lifelong infections despite the presence of a powerful immune response directed against these viruses. In addition, re-infections of immune individuals may occur, even by the same viral strain. These examples indicate that herpesviruses have acquired powerful immune evasion mechanisms. Evasion indeed occurs at multiple levels, targeting both innate and adaptive branches of the immune response. Herpesviruses have been found to affect antiviral host responses by interfering with cytokine and chemokine signaling [4] , by impairing the complement cascade [5] , by preventing natural killer cell-mediated recognition and elimination of infected cells [6] , and by inhibiting innate immune signaling by pattern-recognition receptors, such as Toll-like receptors and RIG-I-like receptors [7] . Furthermore, the past decades have witnessed the elucidation of diverse strategies by which herpesviruses manipulate the host adaptive immune response [8, 9] . These include utilizing herpesvirus-encoded Fc receptors to inhibit antibody-mediated effector mechanisms [10] and subverting the MHC II [11] and, particularly, the MHC I antigen processing and presentation pathways.
Herpesviruses encode a wealth of proteins specifically interfering with MHC I-restricted antigen presentation. More recently, also poxviruses have been found to actively evade MHC I-restricted CTLs through a series of specialized gene products. The characteristics of these immune evasion proteins, their deployment during evolutionary combat, their remarkably distinct mechanisms of action, and their application as versatile tools in antigen presentation studies are discussed in this review.
The MHC I antigen presentation pathway is a prime target for viral immune evasion Herpesvirus immune evasion strategies appear to target each step of the MHC I presentation pathway (Figure 1 ). The gammaherpesviruses EBV and KSHV encode the latency-associated proteins EBNA1 and LANA, respectively, which interfere with their own translation and with their proteasomal degradation, thereby reducing the generation of antigenic peptides [12, 13, 41] . Alphaherpesviruses and gammaherpesviruses express shutoff proteins that block host protein synthesis, with new MHC I molecules being among the host proteins that are affected [14] [15] [16] [17] [18] . The Viral Inhibitor of Heavy Chain Expression or VIHCE protein of rhesus CMV (RhCMV) specifically inhibits the synthesis of MHC I heavy chains in a signal peptide-dependent fashion through a yet enigmatic mechanism [19 ] . complexes are present in phagosomal compartments, facilitating translocation of peptides into those compartments for (cross-)presentation by MHC I molecules [30,31 ,34 ]. In a number of studies, dislocation of proteins was found to involve the Sec61 complex, analogous to HCMV US2 and US11-mediated retrotranslocation of MHC I HC [30,31
,33].
The role of the dislocation pathway in antigen processing is further illustrated by tyrosinase, a melanocyte differentiation protein that is a target for melanoma-reactive T cells [35] . Glycoproteins that are dislocated from the ER back to the cytosol lose their N-linked glycans in a reaction that is catalyzed by a cytoplasmic N-glycanase. This deglycosylation involves the deamidation of asparagines, changing these amino acids into aspartic acid. The presence of an aspartic acid residue within a T cell epitope of tyrosinase at a position where the native protein carries an asparagine residue witnesses the involvement of the cytosolic N-glycanase, and thus ER-tocytosol dislocation, as an essential step in the processing of this particular epitope [36] . Deamidation has been found for several other T cell epitopes, including epitopes derived from HIV-1 env, hepatitis C virus E1, and lymphocytic choriomeningitis virus (LCMV) GP1 [36], suggesting a wide role for protein dislocation in antigen presentation.
Another important cellular process that is manipulated by viruses in many ways is the ubiquitin system. Herpesviruses code for E3 ubiquitin ligases, such as HSV ICP0, KSHV kK3 and kK5, and MHV68 mK3, but also for numerous de-ubiquitinating enzymes. The intriguing interplay between viruses and the ubiquitin system has been reviewed by Isaacson and Ploegh [37] . An example of an interesting, novel phenomenon discovered in the context of herpesvirus immune evasion pertains to ubiquitin conjugation by the E3 ligases mK3 and kK3/kK5 of MHV68 and KSHV, respectively. These proteins catalyze the ubiquitination of cytoplasmic domains of MHC I HC, resulting in the proteasomal degradation (in case of MHV68) or endocytosis (in case of KSHV) of MHC I molecules [8] . When the amino acid residues that are ubiquitinated were identified within the MHC I HC, it was found that in addition to the common ubiquitin acceptor lysine, also cysteine, serine, and threonine residues were ubiquitinated [38 ,39
,40 ]. These findings implicate a novel chemical mechanism of substrate ubiquitination via ester linkages. Most probably, cysteine, serine, and threonine ubiquitination is used more widely by the cell. The functional implications of this particular type of conjugation are yet to be determined.
Viral immune evasion proteins: valuable tools in antigen presentation studies
EBV EBNA1 and KSHV LANA carry large repeats of glycine-alanine and serine-proline residues, respectively, that hamper proteasomal degradation of these viral gene products [13, 41] . When transferred to other proteins, the repeats effectively block degradation of these proteins in cis. Thus, they can be used to inhibit the first stage of the MHC I presentation pathway, namely the generation of antigenic peptides by proteasomes [41, 42] . EBNA1 has also been instrumental in uncovering the role of autophagy in antigen presentation. Using EBNA1 as a model antigen, autophagy was found to allow MHC II-mediated presentation of peptides derived from a nuclear or cytosolic protein [43 ,44 ] .
Herpesvirus-encoded TAP inhibitors have been particularly useful in cross-presentation studies aiming to unravel the routes by which exogenous antigens are loaded onto MHC I molecules. A 35-residue peptide encompassing the TAP-inhibiting domain of HSV ICP47 has been shown to be endocytosed and to subsequently block TAP function [31 ] . Since ICP47 interferes with the binding of peptides to cytosolic domains of TAP, this finding implies that extracellular proteins can reach the cytosol of cells, possibly via the Sec61 dislocation pathway (discussed above) [30, 45] . The ICP47 peptide inhibits both direct and cross-presentation, implicating the involvement of TAP in cross-presentation. HCMV US6 inhibits TAP by interacting with ER-luminal domains of TAP. Exposure of DCs to a soluble form of US6 completely abrogates cross-presentation, confirming the essential role for TAP in cross-presentation [34 ,46] . At the same time, these experiments show the existence of a connection between the extracellular milieu and TAP-containing compartments and illustrate the contribution of phagosomes and pinosomes to presentation of exogenous antigens by DCs. Selective deposition of US6 into early endosomes using a US6-transferrin fusion protein identified these endosomes as loading compartments for cross-presented peptides derived from soluble antigens [32 ] .
The herpesvirus-encoded TAP inhibitors each act in a unique way, targeting different stages of the peptide translocation cycle (summarized in Table 1 ). ICP47 and EBV-encoded BNLF2a block binding of substrates to the cytosolic peptide binding site of TAP; US6, BNLF2a, and the UL49.5 proteins of equine herpesvirus 1 and 4 affect the association of ATP with the nucleotide binding domains of TAP; US6 and the UL49.5 proteins of all TAP-inhibiting varicelloviruses interfere with conformational transitions required for translocation of peptides over the ER membrane, and UL49.5 of bovine herpesvirus 1 and related ruminant varicelloviruses target TAP for proteasomal degradation [47] [48] [49] [50] [51] [52] [53] [54] 55 ] . Recently, the cowpox protein CPX V012 was identified as a TAP inhibitor [25 ,26 ] . The mechanism by which this protein blocks TAP-mediated peptide transport has not yet been resolved.
The viral TAP inhibitors can be used to block the peptide translocation cycle at different stages and therefore are valuable tools to study the molecular biophysics of peptide translocation by TAP. In addition, viral TAP inhibitors may be used to freeze TAP at intermediate stages of the translocation cycle, which may be informative when resolving the crystal structure of the peptide transporter [56, 57] . Elucidation of the molecular mechanisms underlying viral TAP inhibition will facilitate the use of TAP inhibitors for selective immune suppression in the context of, for example, auto-immune diseases and tissue and organ transplantation. In addition, this knowledge may aid the development of substances blocking other ABC transporters, for example those responsible for multiple drug resistance in bacterial and cancer cells.
In vivo implications of viral stealth technology
Recently, several interesting studies have highlighted the importance of viral immune evasion mechanisms in the life cycle of viruses in vivo. In addition, animal studies have been initiated to explore the applications of viral immune evasion proteins for the rational design of novel strategies for vaccine development, cancer treatment, transplant protection, and gene therapy.
Using RhCMV as a model, Hansen et al. have shown that the evasion molecules encoded by the US region of this virus (e.g. US2, US3, US6, and US11) are dispensable for primary infection and persistence of the virus, but are essential for superinfection of a CMV-immune host [58 ] . The in vivo relevance of viral T cell immune evasion proteins has been demonstrated for two other viruses as well, namely cowpox virus and MHV68. An elegant study by Byun and colleagues demonstrated the biological function of two cowpox virus-encoded inhibitors of MHC I-restricted antigen presentation, CPX V012 and CPX V203 [25 ] . Deletion of the genes encoding these evasion proteins restored MHC I surface expression and T cell stimulation in vitro and reduced virulence in mice, thus demonstrating the significance of these immune evasion proteins in one of the virus' natural host species. For MHV68, deletion of the MHC I inhibitor mK3 increased CTL responses to lytic viral proteins, without major effects on viral replication. By contrast, removal of mK3 resulted in decreased latent viral loads, suggesting a role for immune evasion in amplifying the latent reservoir for this herpesvirus [59] .
The capacity of herpesviruses to superinfect immune hosts, and to induce and maintain strong T cell immunity makes these viruses promising vaccine vectors. The potential of this approach has been demonstrated in a landmark study by Hansen et al., who used RhCMV as a carrier virus for immunization against simian immunodeficiency virus infection [60 ] .
Alternative applications of viral stealth technology in the fields of transplant protection and cancer therapy have been reviewed by Horst et al. [61] . An interesting example is the use of viral TAP inhibitors to induce T cells recognizing an alternative peptide repertoire carried by tumor cells with antigen processing defects [62 ] . MHC I molecules of tumor cells with deficiencies in the MHC I presentation pathway carry a repertoire of subdominant T cell epitopes, named T cell Epitopes associated with Impaired Peptide Processing (TEIPP). T cells directed against TEIPP can be selected in vitro using antigen presenting cells expressing viral TAP inhibitors such as the bovine herpesvirus 1 UL49.5 protein. These TEIPP-specific T cells protect mice against the outgrowth of TAP-deficient lymphomas and fibrosarcomas [63 ] .
Viral stealth technology also holds promise in gene therapy, providing tools to improve the survival of cells expressing a transgene, which often represents a neoantigen (reviewed by Horst et al.) [61] .
Conclusions
Large DNA viruses, such as herpesviruses and poxviruses, dedicate a considerable part of their genome to immune evasion. The MHC I antigen processing and presentation pathway appears to be a prime target for viral evasion, illustrating the evolutionary pressure exerted by CD8 + CTLs during co-evolution of these viruses with their hosts. Viral immune evasion proteins target virtually every step in the MHC I pathway and therefore constitute powerful tools for antigen processing and presentation research. The power of this approach has been demonstrated in studies in which TAP inhibitors have been used 
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